HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Hematology21 papers

Myelodysplastic/myeloproliferative disease

Last edited: 4/15/2026

Overview

Myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) represent a rare group of bone marrow disorders characterized by overlapping features of dysplastic and proliferative pathologies, leading to bone marrow failure and myeloproliferation with generally poor prognosis 12.

Diagnosis

  • Clinical Features: Concurrent bone marrow failure and myeloproliferation 2.
  • Morphology and Cytology: Bone marrow biopsy showing dysplastic changes alongside hypercellularity and atypical cell populations 2.
  • Molecular Markers: Emerging genetic studies highlight specific mutations that may aid in diagnosis and classification 2.
  • Flow Cytometry: Essential for identifying atypical cell populations and lineage involvement 2.
  • Imaging: Not typically required for diagnosis but may be used to assess extramedullary hematopoiesis 2.
  • Laboratory Tests: Comprehensive blood counts, peripheral smear examination, and functional assessments of blood cell lines 2.

    • Management

  • First-Line Treatments: Specific drug classes and doses are not detailed in the provided abstracts; however, targeted therapies based on genetic profiles are anticipated 2.
  • Adjunctive Therapies: Supportive care including transfusions, antibiotics, and management of cytopenias 2.
  • Clinical Trials: Participation in trials testing new drugs tailored to MDS/MPN overlap syndromes is encouraged 1.

    • Special Populations

  • Elderly Patients: Management often focuses on supportive care due to poor tolerance of aggressive therapies 2.
  • Comorbidities: Tailored treatment approaches considering the impact of comorbidities on overall prognosis and treatment tolerance 2.

    • Key Recommendations

  • Develop and adopt uniform response criteria for clinical trials in MDS/MPNs to improve comparability of treatment outcomes (Evidence: Expert opinion) 1.
  • Incorporate advanced genetic testing in the diagnostic workup to better classify and predict outcomes in MDS/MPN patients (Evidence: Moderate) 2.
  • Consider enrollment in clinical trials evaluating novel therapeutic agents for MDS/MPNs, given the rarity and poor prognosis of these syndromes (Evidence: Expert opinion) 1.

    • References

    1 Steensma DP. Speaking a common language in MDS/MPNs. Blood 2015. link 2 Padron E. Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?. Hematology. American Society of Hematology. Education Program 2015. link

    Original source

    1. [1]
      Speaking a common language in MDS/MPNs. — Steensma DP Blood (2015)
    2. [2]
      Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes? — Padron E Hematology. American Society of Hematology. Education Program (2015)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG